Drugs / ZG005
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/210 trials | ||||||
| Phase 1/2 | NCT07038096 | Sep 2025 → Sep 2027 expected | small cell lung carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07080216 | Sep 2025 → Aug 2027 expected | cervical cancer | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07142837 | Sep 2025 → Oct 2027 expected | neoplasm | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06903377 | May 2025 → Apr 2027 expected | non-small cell lung carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06938880 | May 2025 → May 2027 expected | neoplasm | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06883526 | May 2025 → Apr 2027 expected | lymphoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06372626 | May 2024 → Jul 2026 overdue | neuroendocrine carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06239298 | May 2024 → Mar 2026 | neoplasm | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Unknown | No outcome recorded |
| Phase 1/2 | NCT06241235 | Mar 2024 → May 2026 | cervical carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Unknown | No outcome recorded |
| Phase 1/2 | NCT06233292 | Jun 2022 → Jan 2026 | cancer | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07099547 | Dec 2025 → Dec 2027 expected | biliary tract cancer | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT06927687 | Jun 2025 → May 2027 expected | neoplasm | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06558227 | Oct 2024 → Sep 2026 overdue | hepatocellular carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07833839 | Oct 2026 → Oct 2031 expected | neuroendocrine carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07813572 | Sep 2026 → Sep 2031 expected | hepatocellular carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06233994 | Jan 2024 → Jan 2026 | hepatocellular carcinoma | Changsha Taihe Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Results 2026 ASCO I 泽璟制药发布ZG005和ZG006临床数据及最新进展 zelgen.com ↗ |
| 2025-06-02 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Results 2025 ASCO I 泽璟制药发布ZG006和ZG005临床数据及最新进展 zelgen.com ↗
ORR为50%，DCR为91.7%. |
| 2024-12-25 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Regulatory 泽璟制药注射用ZG005与盐酸吉卡昔替尼片联用的临床试验获得国家药监局批准 zelgen.com ↗
近日 ，泽璟 制药 收到 国家 药监 局核 准签 发的 《药物 临床 试验 批准 通知 书》，注射 用ZG005与盐 酸吉 卡昔 替尼 片联 合分 别用 于晚 期实 体瘤 和复 发难 治性 淋巴 瘤的 临床 试验 获得 批准 . |
| 2024-09-25 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Results 2024 CSCO I 泽璟制药发布ZG005和ZG006临床研究数据 zelgen.com ↗ |
| 2024-05-24 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Results ASCO 2024 I 泽璟制药发布ZG005和ZGGS18临床数据及最新进展 zelgen.com ↗
有效 性方 面，可评 估疗 效的 21例宫 颈癌 受试 者（3 mg/kg组1例、10 mg/kg组12例、20 mg/kg组8例）中，有2例完 全缓 解（CR）、7例部 分缓 解（PR）和8例疾 病稳 定（SD）；客观 缓解 率（ORR）为43%（9/21），疾病 控制 率（DCR）为81%（17/21）. |
| 2023-09-21 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Regulatory 泽璟制药ZG005粉针剂与甲苯磺酸多纳非尼片联用的临床试验获得国家药监局批准 zelgen.com ↗
近日 ，泽璟 制药 收到 国家 药监 局核 准签 发的 《药物 临床 试验 批准 通知 书》，ZG005粉针 剂与 甲苯 磺酸 多纳 非尼 片（商品 名：泽普 生®，以下 简称 “多纳 非尼 ”）联合 用于 实体 肿瘤 的临 床试 验获 得批 准. |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2026 ASCO I 泽璟制药发布ZG005和ZG006临床数据及最新进展 zelgen.com ↗ |
| 2025-06-02 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2025 ASCO I 泽璟制药发布ZG006和ZG005临床数据及最新进展 zelgen.com ↗ |
| 2024-12-25 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 泽璟制药注射用ZG005与盐酸吉卡昔替尼片联用的临床试验获得国家药监局批准 zelgen.com ↗ |
| 2024-09-25 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2024 CSCO I 泽璟制药发布ZG005和ZG006临床研究数据 zelgen.com ↗ |
| 2024-05-24 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | ASCO 2024 I 泽璟制药发布ZG005和ZGGS18临床数据及最新进展 zelgen.com ↗ |
| 2023-09-21 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 泽璟制药ZG005粉针剂与甲苯磺酸多纳非尼片联用的临床试验获得国家药监局批准 zelgen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZG005 | “ZG005 for dose escalations are set as 10 mg/kg, 15 mg/kg and other doses after discussion” NCT06241235 ↗ |
| Route | Intravenous | “intravenous infusion” NCT06233292 ↗ |